Table 1.
List of publications commenting specifically on heterotopic ossification and hip arthroscopy between 2014 and 2018, inclusive
| Authors | Journal | Year | LOE | Conclusions |
|---|---|---|---|---|
| Beckmann et al. [7•] | AJSM | 2014 | 3; CS |
Prophylactic therapy: 500 mg naproxen BID for 3 weeks. At risk: mixed impingement (osteoplasty, rim trim) Results: no prophylaxis = 16.6 times more chance of HO Complications: ARF, hematochezia, acute colitis/gastritis |
| Uquillas and Youm [8•] | JBJS | 2014 | 5; CR | Small symptomatic lesions may be treated with US-guided pulsed lavage. N = 1 Case study. |
| Amar et al. [9•] | Arthroscopy | 2015 | 3; RR |
Prophylactic therapy: none Results: control group (capsule left open) 44% HO; study group (capsule closure) 28% HO. Not statistically significant |
| Amar et al. [10] | JHPS | 2015 | 5; LR | Review paper outlining incidence, risk factors, diagnosis, prophylactic measures, management of HO in hip arthroscopy. |
| Beckmann et al. [1••] | JBJS | 2015 | 1; RCT |
Prophylactic therapy: 500 mg naproxen BID for 3 weeks Results: study was stopped as the efficacy of naproxen group was clearly demonstrated at midterm analysis (46% HO in placebo vs 4% in naproxen group). Complications: adverse events were equal between placebo and naproxen groups |
| Loken, S [11•] | JBJS—commentary | 2015 | 5; EO | Provides commentary and expert opinion on the above RCT authored by Beckmann et al. Only 1 symptomatic HO pt. was revised due to HO. The rest was radiographic HO. Must consider negative effects on repaired labrum and/or capsule as well as innate NSAID risks. |
| Rath et al. [12•] | AJSM | 2015 | 3; CS |
Prophylactic therapy: 600 mg etodolac (COX-2 inhibitor) daily for 2 weeks. Results: 36% HO in control group (no NSAIDs); 0% HO in study group (etodolac). Complications: 2 discontinued prophylaxis for GI symptoms |
| Yeung et al. [13•] | Arthroscopy | 2016 | 3; SR |
1662 patients investigating NSAIDs prophylaxis in hip arthroscopy. Prophylactic therapy: variable Results: incidence 13.4% HO without NSAIDs, 3.3% HO with NSAIDs prophylaxis. Most patients were asymptomatic. Complications: not consistently reported. |
| Miller, GK [14•] | Arthroscopy—commentary | 2016 | 5; EO | Provides commentary and expert opinion on the above systematic review authored by Yeung et al. Must consider negative effects NSAIDs when using as prophylaxis. Low rate of symptomatic HO post-hip arthroscopy. |
| Redmond et al. [15•] | JHPS | 2017 | 3; RR |
Prophylactic therapy: aspirin 325 mg BID for 6 weeks Results: revision hip arthroscopy for HO excision demonstrated overall improvement; however, few achieved good to excellent results. Complications: 21% conversion to THA or re-revision hip scope. |
| Warschawski et al. [16•] | JOCR | 2017 | 5; CR |
Prophylactic therapy: left hip (none), right hip (etodolac 600 mg daily for 2 weeks) Results: grade 3 HO on the left hip (asymptomatic), no HO on the right hip. Suggests routine HO prophylaxis. Complications: Nil, N = 1 case study. |
| Barth et al. [17] | JOSPT | 2018 | 5; CR |
Prophylactic therapy: non-specific Re-revised for HO excision, with indomethacin post-op and pain resolved. N = 1 case study. |
AJSM, American Journal of Sports Medicine; JBJS, Journal of Bone and Joint Surgery; Arthroscopy, The Journal of Arthroscopic and Related Surgery; JOSPT, Journal of Orthopedics and Sports Physical Therapy; JHPS, Journal of Hip Preservation Surgery; JOCR, Journal of Orthopedic Case Reports; CS, cohort study; CR, case report; RCT, randomized controlled trial; SR, systematic review; RR, retrospective review; EO, expert opinion; LR, literature review